World Journal of Surgery

, 30:2112

Hyperbaric Oxygen Therapy for Malignancy: A Review

Article

Abstract

One unique feature of tumors is the presence of hypoxic regions, which occur predominantly at the tumor center. Hypoxia has a major impact on various aspects of tumor cell function and proliferation. Hypoxic tumor cells are relatively insensitive to conventional therapy owing to cellular adaptations effected by the hypoxic microenvironment. Recent efforts have aimed to alter the hypoxic state and to reverse these adaptations to improve treatment outcome. One way to increase tumor oxygen tensions is by hyperbaric oxygen (HBO) therapy. HBO therapy can influence the tumor microenvironment at several levels. It can alter tumor hypoxia, a potent stimulus that drives angiogenesis. Hyperoxia as a result of HBO also produces reactive oxygen species, which can damage tumors by inducing excessive oxidative stress. This review outlines the importance of oxygen to tumors and the mechanisms by which tumors survive under hypoxic conditions. It also presents data from both experimental and clinical studies for the effect of HBO on malignancy.

References

  1. 1.
    Vaupel P, et al. Blood flow, oxygen consumption and tissue oxygenation of human tumors. Adv Exp Med Biol 1990;277:895–905PubMedGoogle Scholar
  2. 2.
    Tandara AA, et al. Oxygen in wound healing—more than a nutrient. World J Surg 2004;28:294–300PubMedGoogle Scholar
  3. 3.
    Grolman RE, et al. Transcutaneous oxygen measurements predict a beneficial response to hyperbaric oxygen therapy in patients with nonhealing wounds and critical limb ischemia. Am Surg 2001;67:1072–1080PubMedGoogle Scholar
  4. 4.
    Hammarlund C, et al. Hyperbaric oxygen treatment of healthy volunteers with U.V.-irradiated blister wounds. Burns 1991;17:296–301PubMedGoogle Scholar
  5. 5.
    Thom SR, et al. Delayed neuropsychologic sequelae after carbon monoxide poisoning: prevention by treatment with hyperbaric oxygen. Ann Emerg Med 1995;25:474–480PubMedGoogle Scholar
  6. 6.
    Weaver LK, et al. Hyperbaric oxygen for acute carbon monoxide poisoning.N Engl J Med 2002;347:1057–1067PubMedGoogle Scholar
  7. 7.
    Dean BS, et al. Coma reversal with cerebral dysfunction recovery after repetitive hyperbaric oxygen therapy for severe carbon monoxide poisoning. Am J Emerg Med 1993;11:616–618PubMedGoogle Scholar
  8. 8.
    Hawkins M, et al. Severe carbon monoxide poisoning: outcome after hyperbaric oxygen therapy. Br J Anaesth 2000;84:584–586PubMedGoogle Scholar
  9. 9.
    Durmaz E, et al. Carbon monoxide poisoning and hyperbaric oxygen therapy. Br J Nurs 1999;8:1067–1072PubMedGoogle Scholar
  10. 10.
    Wilkinson D, et al. Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg 2004;139:1339–1345PubMedGoogle Scholar
  11. 11.
    Henk JM, et al. Radiotherapy and hyperbaric oxygen in head and neck cancer: final report of first controlled clinical trial. Lancet 1977;2:101–103PubMedGoogle Scholar
  12. 12.
    Petre PM, et al. Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model. J Thorac Cardiovasc Surg 2003;125:85–95PubMedGoogle Scholar
  13. 13.
    Mayer R, et al. Hyperbaric oxygen and radiotherapy. Strahlenther Onkol. 2005;181:113–123PubMedGoogle Scholar
  14. 14.
    DeCosse JJ, et al. Influence of high-pressure oxygen and chemotherapy on the AMel 4 hamster melanoma. Cancer Res 1966;26:287–292PubMedGoogle Scholar
  15. 15.
    Takiguchi N, et al. Use of 5-FU plus hyperbaric oxygen for treating malignant tumors: evaluation of antitumor effect and measurement of 5-FU in individual organs. Cancer Chemother Pharmacol 2001;47:11–14PubMedGoogle Scholar
  16. 16.
    Huang Z, et al. Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy. Photochem Photobiol 2003;78:496-502PubMedGoogle Scholar
  17. 17.
    Moulder JE, et al. Tumor hypoxia: its impact on cancer therapy. Cancer Metastasis Rev 1987;5:313–341PubMedGoogle Scholar
  18. 18.
    Knisely JP, et al. Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin N Am 2002;12:525–536PubMedGoogle Scholar
  19. 19.
    Puffer HW, et al. Preliminary observations of oxygen levels in microcirculation of tumors in C3H mice. Adv Exp Med Biol 1976;75:605–610PubMedGoogle Scholar
  20. 20.
    Kizaka-Kondoh S, et al. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci 2003;94:1021–1028PubMedGoogle Scholar
  21. 21.
    Brizel DM, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Physics 1997;38:285–289Google Scholar
  22. 22.
    Dunst J, et al. Tumor hypoxia and systemic levels of vascular endothelial growth factor (VEGF) in head and neck cancers. Strahlenther Onkol 2001;177:469–473PubMedGoogle Scholar
  23. 23.
    Hockel M, et al. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999;59:4525–4528PubMedGoogle Scholar
  24. 24.
    Cvetkovic D, et al. Increased hypoxia correlates with increased expression of the angiogenesis marker vascular endothelial growth factor in human prostate cancer. Urology 2001;57:821–825PubMedGoogle Scholar
  25. 25.
    Shi Q, et al. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999;3711–3721Google Scholar
  26. 26.
    Cuisnier O, et al. Chronic hypoxia protects against gamma-irradiation-induced apoptosis by inducing bcl-2 up-regulation and inhibiting mitochondrial translocation and conformational change of bax protein. Int J Oncol 2003;23:1033–1041PubMedGoogle Scholar
  27. 27.
    Vaupel P, et al. Tumor oxygenation and its relevance to tumor physiology and treatment. Adv Exp Med Biol 2003;510:45–49PubMedGoogle Scholar
  28. 28.
    Vaupel P, et al. Tumor hypoxia and malignant progression. Methods Enzymol 2004;381:335–354PubMedGoogle Scholar
  29. 29.
    Hockel M, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509–4515PubMedGoogle Scholar
  30. 30.
    Bachtiary B, et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res 2003;9:2234–2240PubMedGoogle Scholar
  31. 31.
    Hashizume H, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363–1380PubMedGoogle Scholar
  32. 32.
    Galmarini CM, et al. Multidrug resistance in cancer therapy: role of the microenvironment. Curr Opin Invest Drugs 2003;4:1416–1421Google Scholar
  33. 33.
    Chaplin DJ, et al. Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res 1987;47:597–601PubMedGoogle Scholar
  34. 34.
    Sakamoto M, et al. Phenotype changes in tumor vessels associated with the progression of hepatocellular carcinoma. Jpn J Clin Oncol 1993;23:98–104PubMedGoogle Scholar
  35. 35.
    Toi M, et al. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994;85:1045–1049PubMedGoogle Scholar
  36. 36.
    Duque JL, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54:523–527PubMedGoogle Scholar
  37. 37.
    Karayiannakis AJ, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003;194:119–124PubMedGoogle Scholar
  38. 38.
    Jacobsen J, et al. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000;163:343–347PubMedGoogle Scholar
  39. 39.
    Akbulut H, et al. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 2002;20:184–190PubMedGoogle Scholar
  40. 40.
    Ikeda E, et al. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995;270:19761–19766PubMedGoogle Scholar
  41. 41.
    Ferrara N, et al. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25PubMedGoogle Scholar
  42. 42.
    Leung DW, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306–1309PubMedGoogle Scholar
  43. 43.
    Horiuchi A, et al. Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Res 2002;22:2697–2702PubMedGoogle Scholar
  44. 44.
    Rofstad EK, et al. Hypoxia-induced angiogenesis and vascular endothelial growth factor secretion in human melanoma. Br J Cancer 1998;77:897–902PubMedGoogle Scholar
  45. 45.
    Ziemer LS, et al. Hypoxia and VEGF mRNA expression in human tumors. Neoplasia 2001;3:500–508PubMedGoogle Scholar
  46. 46.
    Shweiki D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843–845PubMedGoogle Scholar
  47. 47.
    Plate KH, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845–848PubMedGoogle Scholar
  48. 48.
    White FC, et al. VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors 1995;12:289–301PubMedGoogle Scholar
  49. 49.
    Levy AP, et al. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 1995;270:13333–13340PubMedGoogle Scholar
  50. 50.
    Stein I, et al. Translation of vascular endothelial growth factor mRNA by internal ribosome entry: implications for translation under hypoxia. Mol Cell Biol 1998;18:3112–3119PubMedGoogle Scholar
  51. 51.
    Schoch HJ, et al. Hypoxia-induced vascular endothelial growth factor expression causes vascular leakage in the brain. Brain 2002;125:2549–2557PubMedGoogle Scholar
  52. 52.
    Iyer NV, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 1998;12:149–162PubMedGoogle Scholar
  53. 53.
    Wang GL, et al. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995;92:5510–5514PubMedGoogle Scholar
  54. 54.
    Tang N, et al. Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004;6:485–495PubMedGoogle Scholar
  55. 55.
    Forsythe JA, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604–4613PubMedGoogle Scholar
  56. 56.
    Semenza GL, et al. ‘The metabolism of tumours’: 70 years later. Novartis Found Symp 2001;240:251–264PubMedCrossRefGoogle Scholar
  57. 57.
    Kuwabara K, et al. Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc Natl Acad Sci USA 1995;92:4606–4610PubMedGoogle Scholar
  58. 58.
    Hartmann A, et al. Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. Cancer Res 1999;59:1578–1583PubMedGoogle Scholar
  59. 59.
    Chavey C, et al. IL-8 is a novel marker for breast cancer. Third Int Symp Mol Biol Breast Cancer 2005;7(Suppl 2)Google Scholar
  60. 60.
    Benoy IH, et al. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 2004;10:7157–7162PubMedGoogle Scholar
  61. 61.
    Brown NS, et al. Thymidine phosphorylase induces carcinoma cell oxidative stress and promotes secretion of angiogenic factors. Cancer Res 2000;60:6298–6302PubMedGoogle Scholar
  62. 62.
    Kunz M, et al. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma: a potential mechanism for high tumor aggressiveness. Am J Pathol 1999;155:753–763PubMedGoogle Scholar
  63. 63.
    Giri D, et al. Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. Am J Pathol 2001;159:139–147PubMedGoogle Scholar
  64. 64.
    D’Agnano I, et al. DNA ploidy, proliferative index, and epidermal growth factor receptor: expression and prognosis in patients with gastric cancers. Lab Invest 1995;72:432–438PubMedGoogle Scholar
  65. 65.
    Van Schaeybroeck S, et al. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy. Clin Cancer Res 2005;11:7480–7489PubMedGoogle Scholar
  66. 66.
    Oh MJ, et al. Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin Cancer Res 2000;6:4760–4763PubMedGoogle Scholar
  67. 67.
    Gazzaniga P, et al. Detection of epidermal growth factor receptor mRNA in peripheral blood: a new marker of circulating neoplastic cells in bladder cancer patients. clin Cancer Res 2001;7:577–583PubMedGoogle Scholar
  68. 68.
    Graeber TG, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88–91PubMedGoogle Scholar
  69. 69.
    Shaw P, et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992;89:4495–4499PubMedGoogle Scholar
  70. 70.
    Brown NS, et al. Hypoxia and oxidative stress in breast cancer; oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001;3:323–327PubMedGoogle Scholar
  71. 71.
    Bergh J, et al. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1:1029–1034PubMedGoogle Scholar
  72. 72.
    Havrilesky L, et al. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3814–3825PubMedGoogle Scholar
  73. 73.
    Baker SJ, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217–221PubMedGoogle Scholar
  74. 74.
    Chadeneau C, et al. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Camcer Res 1995;55:2533–2536Google Scholar
  75. 75.
    Oishi T, et al. Alteration of telomerase activity associated with development and extension of epithelial ovarian cancer. Obstet Gynecol 1998;91:568–571PubMedGoogle Scholar
  76. 76.
    Kuniyasu H, et al. Expression of human telomerase RNA is an early event of stomach carcinogenesis. Jpn J Cancer Res 1997;88:103–107PubMedGoogle Scholar
  77. 77.
    Kumaki F, et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol 2001;188–195Google Scholar
  78. 78.
    Hiyama K, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995;895–902Google Scholar
  79. 79.
    Minamino T, et al. Hypoxia extends the life span of vascular smooth muscle cells through telomerase activation. Mol Cell Biol 2001;3336–3342Google Scholar
  80. 80.
    Ravi R, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000;14:34–44PubMedGoogle Scholar
  81. 81.
    Koukourakis MI, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001;61:1830–1832PubMedGoogle Scholar
  82. 82.
    Hockenbery D, et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334–336PubMedGoogle Scholar
  83. 83.
    Lowe SW, et al. Apoptosis in cancer. Carcinogenesis 2000;21:485–495PubMedGoogle Scholar
  84. 84.
    Warburg O, et al. On growth of cancer cells in media in which glucose is replaced by galactose. Hoppe Seylers Z Physiol Chem 1967;348:1686–1687PubMedGoogle Scholar
  85. 85.
    Kondo Y, et al. Over expression of hypoxia-inducible factor-1alpha in renal and bladder cancer cells increases tumorigenic potency. J Urol 2005;173:1762–1766PubMedGoogle Scholar
  86. 86.
    Semenza GL, et al. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 1994;269:23757–23763PubMedGoogle Scholar
  87. 87.
    Webster KA, et al. Coordinate reciprocal trends in glycolytic and mitochondrial transcript accumulations during the in vitro differentiation of human myoblasts. J Cell Physiol 1990;142:566–573PubMedGoogle Scholar
  88. 88.
    Maxwell PH, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA 1997;94:8104–8109PubMedGoogle Scholar
  89. 89.
    Bustamante E, et al. High aerobic glycolysis of rat hepatoma cells in culture: role of mitochondrial hexokinase. Proc Natl Acad Sci U S A 1977;74:3735–3739PubMedGoogle Scholar
  90. 90.
    Mathupala SP, et al. Glucose catabolism in cancer cells. Isolation, sequence, and activity of the promoter for type II hexokinase. J Biol Chem 1995;270:16918–16925PubMedGoogle Scholar
  91. 91.
    Lu H, et al. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis: oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Biol Chem 2002;277:23111–23115PubMedGoogle Scholar
  92. 92.
    Dang CV, et al. Oncogenes in tumor metabolism, tumorigenesis, and apoptosis. J Bioenerg Biomembr 1997;29:345–354PubMedGoogle Scholar
  93. 93.
    Elstrom RL, et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004;64:3892–3899PubMedGoogle Scholar
  94. 94.
    Cohen G, et al. Glutathione peroxidase: the primary agent for the elimination of hydrogen peroxide in erythrocytes. Biochemistry 1963;2:1420–1428PubMedGoogle Scholar
  95. 95.
    Talior I, et al. Increased glucose uptake promotes oxidative stress and PKC-delta activation in adipocytes of obese, insulin-resistant mice. Am J Physiol Endocrinol Metab 2003;285:E295–E302PubMedGoogle Scholar
  96. 96.
    McMullin MF. The molecular basis of disorders of red cell enzymes. J Clin Pathol 1999;52:241–244PubMedCrossRefGoogle Scholar
  97. 97.
    Aw TY. Cellular redox: a modulator of intestinal epithelial cell proliferation. News Physiol Sci 2003;18:201–204PubMedGoogle Scholar
  98. 98.
    Kamata H, et al. Redox regulation of cellular signalling. Cell Signal 1999;11:1–14PubMedGoogle Scholar
  99. 99.
    Benhar M, et al. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep 2002;3:420–425PubMedGoogle Scholar
  100. 100.
    Blokhina O, et al. Antioxidants, oxidative damage and oxygen deprivation stress: a review. Ann bot 2003; 91(Spec No):179–194PubMedGoogle Scholar
  101. 101.
    Sharkey S. Current indications for hyperbaric oxygen therapy. Austr Defence Force Health 2000;1:64–72Google Scholar
  102. 102.
    Jackson AL, et al. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 2001;477:7–21PubMedGoogle Scholar
  103. 103.
    Szatrowski TP, et al. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794–798PubMedGoogle Scholar
  104. 104.
    Wiseman H, et al. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J. 1996;313( Pt 1):17–29PubMedGoogle Scholar
  105. 105.
    Kuhn MA. Oxygen free radicals and antioxidants. AJN Am J Nurs 2003;103:58–62Google Scholar
  106. 106.
    Laurent A, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005;65:948–956PubMedGoogle Scholar
  107. 107.
    Behrend L, et al. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003;31:1441–1444PubMedGoogle Scholar
  108. 108.
    Arnold RS, et al. Hydrogen peroxide mediates the cell growth and transformation caused by the mitogenic oxidase Nox1. Proc Natl Acad Sci U S A 2001;98:5550–5555PubMedGoogle Scholar
  109. 109.
    Suh YA, et al. Cell transformation by the superoxide-generating oxidase Mox1. Nature 1999;401:79–82PubMedGoogle Scholar
  110. 110.
    Shen H, et al. Importance of glutathione and associated enzymes in drug response. Oncol Res 1997;9:295–302PubMedGoogle Scholar
  111. 111.
    Harrison LB, et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002;7:492–508PubMedGoogle Scholar
  112. 112.
    Kaelin CM, et al. The effects of hyperbaric oxygen on free flaps in rats. Arch Surg 1990;125:607–609PubMedGoogle Scholar
  113. 113.
    Kong Q, et al. A threshold concept for cancer therapy. Med Hypotheses 2000;55:29–35PubMedGoogle Scholar
  114. 114.
    Hileman EO, et al. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol 2004;53:209–219PubMedGoogle Scholar
  115. 115.
    Portakal O, et al. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem 2000;33:279–284PubMedGoogle Scholar
  116. 116.
    Choi AM, et al. Heme oxygenase-1: function, regulation, and implication of a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir Cell Mol Biol 1996;15:9–19PubMedGoogle Scholar
  117. 117.
    Toyokuni S, et al. Persistent oxidative stress in cancer. FEBS Lett 1995;358:1–3PubMedGoogle Scholar
  118. 118.
    Zhou S, et al. Doxorubicin-induced persistent oxidative stress to cardiac myocytes. Toxicol Lett 2001;121:151–157PubMedGoogle Scholar
  119. 119.
    Gackowski D, et al. Persistent oxidative stress in colorectal carcinoma patients. Int J Cancer 2002;101:395–397PubMedGoogle Scholar
  120. 120.
    Goda N, et al. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003;23:359–369PubMedGoogle Scholar
  121. 121.
    Baish JW, et al. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc Res 1996;51:327–346PubMedGoogle Scholar
  122. 122.
    Alagoz T, et al. Evaluation of hyperbaric oxygen as a chemosensitizer in the treatment of epithelial ovarian cancer in xenografts in mice. Cancer 1995;75:2313–2322PubMedGoogle Scholar
  123. 123.
    Thom SR. Hyperbaric Oxygen Therapy: A Committee Report. Bethesda, Undersea and Hyperbaric Medical Society, 1992;20814Google Scholar
  124. 124.
    Zamboni WA, et al. The effect of acute hyperbaric oxygen therapy on axial pattern skin flap survival when administered during and after total ischemia. J Reconstr Microsurg 1989;5:343–350PubMedGoogle Scholar
  125. 125.
    Erdmann D, et al. Skin allograft rejection and hyperbaric oxygen treatment in immune-histoincompatible mice. Undersea Hyperb Med 1995;22:395–399PubMedGoogle Scholar
  126. 126.
    Granowitz EV, et al. Exposure to increased pressure or hyperbaric oxygen suppresses interferon-gamma secretion in whole blood cultures of healthy humans. Undersea Hyperb Med 2002;29:216–225PubMedGoogle Scholar
  127. 127.
    Marx RE, et al. Relationship of oxygen dose to angiogenesis induction in irradiated tissue. Am J Surg 1990;160:519–524PubMedGoogle Scholar
  128. 128.
    Meltzer T, et al. The effect of hyperbaric oxygen on the bursting strength and rate of vascularization of skin wounds in the rat. Am Surg 1986;52:659–662PubMedGoogle Scholar
  129. 129.
    Feldmeier J, et al. Hyperbaric oxygen: does it promote growth or recurrence of malignancy? Undersea Hyperb Med 2003;30:1–18PubMedGoogle Scholar
  130. 130.
    Hunt TK. The physiology of wound healing. Ann Emerg Med 1988;17:1265–1273PubMedGoogle Scholar
  131. 131.
    Marx RE, et al. Studies in the radiobiology of osteoradionecrosis and their clinical significance. Oral Surg Oral Med Oral Pathol 1987;64:379–390PubMedGoogle Scholar
  132. 132.
    Marx RE, Johnson RP. Problem wounds in oral and maxillofacial surgery: the role of hyperbaric oxygen. In: Davis IC, Hunt TK, editors, Problem Wounds: the Role of Oxygen. New York, Elsevier, 1988; 65–123Google Scholar
  133. 133.
    Phillips SJ. Physiology of wound healing and surgical wound care. ASAIO J 2000;46:S2–S5PubMedGoogle Scholar
  134. 134.
    Conconi MT, et al. Effects of hyperbaric oxygen on proliferative and apoptotic activities and reactive oxygen species generation in mouse fibroblast 3T3/J2 cell line. J Invest Med 2003;51:227–232Google Scholar
  135. 135.
    Lian QL, et al. Effects of hyperbaric oxygen on S-180 sarcoma in mice. Undersea Hyperb Med 1995;22:153–160PubMedGoogle Scholar
  136. 136.
    Johnson RJR, Lauchlan SC. Epidermoid carcinoma of the cervix treated by 60Co therapy and hyperbaric oxygen. In: Proceedings of the third International Congress on Hyperbaric Medicine, 1966;648–652Google Scholar
  137. 137.
    Shewell J, et al. The effect of hyperbaric oxygen treatment on pulmonary metastasis in the C3H mouse. Eur J Cancer (Oxf) 1980;16:253–259Google Scholar
  138. 138.
    McMillan T, et al. The effect of hyperbaric oxygen on oral mucosal carcinoma. Laryngoscope 1989;99:241–244PubMedGoogle Scholar
  139. 139.
    Valaitis J, et al. Effect of hyperbaric oxygen and nitrogen mustard (NSC-762) on Ehrlich ascites tumor. Cancer Chemother Rep 1968;52(Pt 1):405–412PubMedGoogle Scholar
  140. 140.
    Cade IS, et al. Megavoltage radiotherapy in hyperbaric oxygen: a controlled trial. Cancer 1967;20:817–821PubMedGoogle Scholar
  141. 141.
    Eltorai I, et al. Does hyperbaric oxygenation provoke an occult carcinoma in man? In: Proceedings of the VIII International Conference on Hyperbaric Medicine, North Carolina, 1987;18–27Google Scholar
  142. 142.
    Bean JW, et al. Reaction of Ehrlich ascites cells in exposure to oxygen at high pressure. Cancer Res 1966;26:2380–2385PubMedGoogle Scholar
  143. 143.
    McCredie JA, et al. Effects of hyperbaric oxygen on growth and metastases of the C3HBA tumor in the mouse. Cancer 1966;19:1537–1542PubMedGoogle Scholar
  144. 144.
    Suit HD, et al. Effect of daily exposure to high pressure oxygen on tumor growth. Am J Roentgenol Radium Ther Nucl Med 1966;97:1019–1022PubMedGoogle Scholar
  145. 145.
    Johnson RE, et al. Hyperbaric oxygen effect on experimental tumor growth. Radiology 1967;88:775–777PubMedGoogle Scholar
  146. 146.
    Feder BH, et al. The effect of hyperbaric oxygen on pulmonary metastases in C3H mice. Radiology 1968;90:1181–1184PubMedGoogle Scholar
  147. 147.
    Johnson RJR, et al. The effect of hyperbaric oxygen on tumor metastases in mice. Clin Radiol 1971;22:538–540PubMedGoogle Scholar
  148. 148.
    Mestrovic J, et al. Suppression of rat tumor colonies in the lung by oxygen at high pressure is a local effect. Clin Exp Metastasis 1990;8:113–119PubMedGoogle Scholar
  149. 149.
    Dettmer CM, et al. The effect of increased oxygen tensions upon animal tumor growth. Am J Roentgenolo Radium Ther Nucl Med 1968;102:804–810Google Scholar
  150. 150.
    Bradfield JJ, et al. Rapid progression of head and neck squamous carcinoma after hyperbaric oxygenation. Otolaryngol Head Neck Surg 1996;114:793–797PubMedGoogle Scholar
  151. 151.
    Van den Brenk HA, et al. An analysis of the progression and development of metastases in patients receiving x-radiation in hyperbaric oxygen. Clin Radiol 1967;18:54–61PubMedGoogle Scholar
  152. 152.
    Dische S. Hyperbaric oxygen: the Medical Research Council trials and their clinical significance. Br J Radiol 1978;51:888–894PubMedGoogle Scholar
  153. 153.
    Perrins DJD, Wiernik G. Controlled trials in carcinoma of the bladder. In: Smith G, editor, Proceedings of the Sixth International Congress on Hyperbaric Medicine. Aberdeen, Scotland, University Press, 1977;253–258Google Scholar
  154. 154.
    Henk JM. Late results of a trial of hyperbaric oxygen and radiotherapy in head and neck cancer: a rationale for hypoxic cell sensitizers? Int J Radiat Oncol Biol Phys 1986;12:1339–1341PubMedGoogle Scholar
  155. 155.
    Sealy R, et al. Irradiation with misonidazole and hyperbaric oxygen: final report on a randomized trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1986;12:1343–1346PubMedGoogle Scholar
  156. 156.
    Granstrom G. Hyperbaric oxygen therapy decreases the rejection rate of osseointegrated implants after radiotherapy. Strahlenther Onkol 1996;172:20–21PubMedGoogle Scholar
  157. 157.
    Maier A, et al. Combined photodynamic therapy and hyperbaric oxygenation in carcinoma of the esophagus and the esophago-gastric junction. Eur J Cardiothorac Surg 2000;18:649–655PubMedGoogle Scholar
  158. 158.
    Gray LH, et al. The concentration of oxygen dissolved in tissue at the time or irradiation as factor in radiotherapy. Br J Radiol 1953;26:638PubMedCrossRefGoogle Scholar
  159. 159.
    Chen Q, et al. Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol 2002;76:197–203PubMedGoogle Scholar
  160. 160.
    Teicher BA, et al. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73–81PubMedGoogle Scholar
  161. 161.
    Evans JC. Metastasis following radiotherapy in hyperbaric oxygen. Radiology 1969;93:1155–1157PubMedGoogle Scholar
  162. 162.
    Martin DF, et al. Enhancement of tumor radiation response by the combination of a perfluorochemical emulsion and hyperbaric oxygen. Int J Radiat Oncol Biol Phys 1987;747–751Google Scholar
  163. 163.
    Frid IA, et al. Effects of hyperbaric oxygenation on tumor growth. Vopr Onkol 1989;35:970–973PubMedGoogle Scholar
  164. 164.
    Granstrom G, Westin T, Lyden E, Bengt C, Magnusson BG, Edstrom S. Hyperbaric oxygenation does not stimulate experimental tumour growth. In: Proceedings from the XVIth EUBS meeting, Amsterdam, 1990;121–129Google Scholar
  165. 165.
    Headley DB, et al. The effect of hyperbaric oxygen on growth of human squamous cell carcinoma xenografts. Arch Otolaryngol Head Neck Surg 1991;117:1269–1272PubMedGoogle Scholar
  166. 166.
    Sklizovic D, et al. Hyperbaric oxygen therapy and squamous cell carcinoma cell line growth. Head Neck 1993;15:236–240PubMedGoogle Scholar
  167. 167.
    McDonald KR, et al. Effect of hyperbaric oxygenation on existing oral mucosal carcinoma. Laryngoscope 1996;106:957–959PubMedGoogle Scholar
  168. 168.
    Shi Y, et al. Effects of hyperbaric oxygen exposure on experimental head and neck tumor growth, oxygenation, and vasculature. Head Neck 2005;27:362–369PubMedGoogle Scholar
  169. 169.
    Johnson RJ, et al. Sequential study on the effect of the addition of hyperbaric oxygen on the 5 year survival rates of carcinoma of the cervix treated with conventional fractional irradiations. Am J Roentgenol Radium Ther Nucl Med 1974;120:111–117PubMedGoogle Scholar
  170. 170.
    Bennett MB, Sealy R, Hockly J. The treatment of stage III squamous cell carcinoma of the cervix in air and in hyperbaric oxygen. In: Smith G, editor, Proceedings of the Sixth International Congress on Hyperbaric Oxygen. Aberdeen, Scotland, University press, 1977;247–252Google Scholar
  171. 171.
    Henk JM, et al. Radiotherapy and hyperbaric oxygen in head and neck cancer: interim report of second clinical trial. Lancet 1977;2:104–105PubMedGoogle Scholar
  172. 172.
    Watson ER, et al. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the cervix. Br J Radiol 1978;51:879–887PubMedGoogle Scholar
  173. 173.
    Brady LW, et al. Hyperbaric oxygen therapy for carcinoma of the cervix—stages IIB, IIIA, IIIB and IVA: results of a randomized study by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1981;7:991–998PubMedGoogle Scholar
  174. 174.
    Granstrom G. Tumor recurrence and development of new head and neck cancers after HDO2—treatment a prospective clinical study. In: Proceedings: International Joint Meeting on Hyperbaric and Underwater Medicine, Milan, 1996;47–60Google Scholar
  175. 175.
    Dische S, et al. Carcinoma of the cervix and the use of hyperbaric oxygen with radiotherapy: a report of a randomised controlled trial. Radiother Oncol 1999;53:93–98PubMedGoogle Scholar
  176. 176.
    Haffty BG, et al. Radiation therapy with hyperbaric oxygen at 4 atmospheres pressure in the management of squamous cell carcinoma of the head and neck: results of a randomized clinical trial: carcinoma of the larynx treated with hypofractionated radiation and hyperbaric oxygen: long-term tumor control and complications. Cancer J Sci Am 1999;5:341–347PubMedGoogle Scholar
  177. 177.
    Haffty BG, et al. Carcinoma of the larynx treated with hypofractionated radiation and hyperbaric oxygen: long-term tumor control and complications. Int J Radiat Oncol Biol Phys 1999;45:13–20PubMedGoogle Scholar
  178. 178.
    Kohshi K, et al. Effects of radiotherapy after hyperbaric oxygenation on malignant gliomas. Br J Cancer 1999;80:236–241PubMedGoogle Scholar
  179. 179.
    Feldmeier JJ, et al. Hyperbaric oxygen an adjunctive treatment for delayed radiation injuries of the abdomen and pelvis. Undersea Hyperb Med 1996;23:205–213PubMedGoogle Scholar
  180. 180.
    Horsman M, et al. The Oxygen Effect: Basic Clinical Radiobiology, 2nd edition. London, Arnold, 1997Google Scholar
  181. 181.
    Overgaard J, et al. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10–21PubMedGoogle Scholar
  182. 182.
    Lartigau E, at al. Hyperbaric oxygen in the treatment of radio-induced lesions in normal tissues. Presented to the European Society for Therapuetic Radiology and Oncology and European Committee for Hyperbaric Medicine, Lisbon, 2001Google Scholar
  183. 183.
    Kalns J, et al. The effect of hyperbaric oxygen on growth and chemosensitivity of metastatic prostate cancer. Anticancer Res 1998;18:363–367PubMedGoogle Scholar
  184. 184.
    Stuhr LE, et al. Hyperbaric oxygen alone or combined with 5-FU attenuates growth of DMBA-induced rat mammary tumors. Cancer Lett 2004;210:35–40PubMedGoogle Scholar
  185. 185.
    Narkowicz CK, et al. Hyperbaric oxygen therapy increases free radical levels in the blood of humans. Free Radic Res Commun 1993;19:71–80PubMedGoogle Scholar
  186. 186.
    Dennog C, et al. Analysis of oxidative DNA damage and HPRT mutations in humans after hyperbaric oxygen treatment. Mutat Res 1999;431:351–359PubMedGoogle Scholar
  187. 187.
    Kalns JE, et al. Exposure to hyperbaric oxygen induces cell cycle perturbation in prostate cancer cells. In Vitro Cell Dev Biol Anim 1999;35:98–101PubMedGoogle Scholar
  188. 188.
    Teas J, et al. Can hyperbaric oxygen therapy reduce breast cancer treatment-related lymphedema? A pilot study. J Womens Health (Larchmt) 2004;13:1008–1018CrossRefGoogle Scholar
  189. 189.
    Yarnold J. Phase II randomized study of hyperbaric oxygen therapy versus standard management in women with chronic arm lymphedema after radiotherapy for early breast cancer. Clinical trial in progress, UK, 2004Google Scholar
  190. 190.
    Maier A, et al. Does hyperbaric oxygen enhance the effect of photodynamic therapy in patients with advanced esophageal carcinoma? A clinical pilot study. Endoscopy 2000;32:42–48PubMedGoogle Scholar
  191. 191.
    Tomaselli, et al. Acute effects of combined photodynamic therapy and hyperbaric oxygenation in lung cancer—a clinical pilot study. Lasers Surg Med 2001;28:399–403Google Scholar

Copyright information

© Société Internationale de Chirurgie 2006

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of Melbourne, Austin HospitalHeidelbergAustralia

Personalised recommendations